Fosmanogepix (APX001) is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis.
There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium Manogepix (MGX, APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of glycosylphosphatidylinositol-anchored mannoproteins in fungi. We evaluated the in vitro activity of MGX and the efficacy of the prodrug fosmanogepix (APX001) in immunosuppressed murine models of hematogenously disseminated fusariosis and pulmonary scedosporiosis. The MGX minimum effective concentration (MEC) for Scedosporium isolates was 0.03 μg/ml, and 0.015 - 0.03 μg/ml for Fusarium isolates. In the scedosporiosis model, treatment of mice with 78 and 104 mg/kg fosmanogepix, along with 1-aminobenzotriazole (ABT) to enhance the serum half-live of MGX, significantly increased median survival time vs. placebo from 7 days to 13 and 11 days, respectively. Furthermore, administration of 104 mg/kg fosmanogepix resulted in a ∼2 log10 reduction in lung, kidney or brain conidial equivalents/gram (CE). Similarly, in the fusariosis model, 78 mg/kg and 104 mg/kg of fosmanogepix plus ABT enhanced median survival time from 7 days to 12 and 10 days, respectively. A 2-3 log10 reduction in kidney and brain CE was observed. In both models, reduction in tissue fungal burden was corroborated with histopathological data with target organs showing reduced or no abscesses in fosmanogepix treated mice. The survival and tissue clearance were comparable to a clinically relevant high dose of liposomal amphotericin B dose (10-15 mg/kg). Our data support the continued development of fosmanogepix as a first in class treatment for infections caused by these rare molds.